Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Hsu

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Modern Rheumatology|January 17, 2018
Efficacy and safety of sirukumab in Japanese patients with moderate to severe rheumatoid arthritis inadequately controlled by disease modifying anti-rheumatic drugs: Subgroup analysis of a phase 3 studyTsutomu Takeuchi, Yoshiya Tanaka, Hisashi Yamanaka, et al.
Modern Rheumatology|March 14, 2018
Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T)Yoshiya Tanaka, Tsutomu Takeuchi, Masayoshi Harigai, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 2, 2018
Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumabChuanpu Hu, Yan Xu, Yanli Zhuang, et al.
Annals of the Rheumatic Diseases|April 26, 2019
Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trialKristen Sweet, Bidisha Dasgupta, Dick de Vries, et al.
The Journal of Rheumatology|November 3, 2016
Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing SpondylitisJonathan Kay, Roy Fleischmann, Edward Keystone, et al.
Annals of the Rheumatic Diseases|October 21, 2011
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE studyJürgen Braun, Atul Deodhar, Robert D Inman, et al.
Advances in Therapy|December 4, 2016
Sirukumab: A Potential Treatment for Mood Disorders?Aileen J Zhou, Yena Lee, Giacomo Salvadore, et al.
Rheumatology (Oxford, England)|October 2, 2012
Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE)Désirée van der Heijde, Jürgen Braun, Atul Deodhar, et al.
Arthritis Research & Therapy|March 9, 2018
Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patientsTsutomu Takeuchi, Hisashi Yamanaka, Masayoshi Harigai, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2016
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus NephritisBrad H Rovin, Ronald F van Vollenhoven, Cynthia Aranow, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Modern Rheumatology|January 17, 2018
Efficacy and safety of sirukumab in Japanese patients with moderate to severe rheumatoid arthritis inadequately controlled by disease modifying anti-rheumatic drugs: Subgroup analysis of a phase 3 studyTsutomu Takeuchi, Yoshiya Tanaka, Hisashi Yamanaka, et al.
Modern Rheumatology|March 14, 2018
Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T)Yoshiya Tanaka, Tsutomu Takeuchi, Masayoshi Harigai, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 2, 2018
Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumabChuanpu Hu, Yan Xu, Yanli Zhuang, et al.
Annals of the Rheumatic Diseases|April 26, 2019
Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trialKristen Sweet, Bidisha Dasgupta, Dick de Vries, et al.
The Journal of Rheumatology|November 3, 2016
Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing SpondylitisJonathan Kay, Roy Fleischmann, Edward Keystone, et al.
Annals of the Rheumatic Diseases|October 21, 2011
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE studyJürgen Braun, Atul Deodhar, Robert D Inman, et al.
Advances in Therapy|December 4, 2016
Sirukumab: A Potential Treatment for Mood Disorders?Aileen J Zhou, Yena Lee, Giacomo Salvadore, et al.
Rheumatology (Oxford, England)|October 2, 2012
Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE)Désirée van der Heijde, Jürgen Braun, Atul Deodhar, et al.
Arthritis Research & Therapy|March 9, 2018
Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patientsTsutomu Takeuchi, Hisashi Yamanaka, Masayoshi Harigai, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2016
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus NephritisBrad H Rovin, Ronald F van Vollenhoven, Cynthia Aranow, et al.
Pageof 5